SABS logo

SAB Biotherapeutics (SABS)

Profile

Full Name

SAB Biotherapeutics, Inc.

Ticker Symbol

SABS

Exchange

NASDAQ

Country

United States

IPO

February 9, 2021

Indexes

Not included

Employees

63

Key Details

Price

$1.23(+4.24%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$3.68(+51.83% YoY)

PE ratio

-

Next earnings date

May 20, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Apr 1, 25 HC Wainwright & Co.
Buy
Apr 1, 25 Chardan Capital
Buy
Jan 29, 25 HC Wainwright & Co.
Buy
Jan 29, 25 Chardan Capital
Buy
Nov 7, 24 Chardan Capital
Buy
Oct 9, 24 Craig-Hallum
Buy
Sep 12, 24 Oppenheimer
Outperform
Sep 9, 24 Chardan Capital
Buy
Aug 28, 24 Oppenheimer
Outperform
Aug 12, 24 HC Wainwright & Co.
Buy

Institutional Ownership

  • What is the ticker symbol for SAB Biotherapeutics?
  • Does SAB Biotherapeutics pay dividends?
  • What sector is SAB Biotherapeutics in?
  • What industry is SAB Biotherapeutics in?
  • What country is SAB Biotherapeutics based in?
  • When did SAB Biotherapeutics go public?
  • Is SAB Biotherapeutics in the S&P 500?
  • Is SAB Biotherapeutics in the NASDAQ 100?
  • Is SAB Biotherapeutics in the Dow Jones?
  • When was SAB Biotherapeutics's last earnings report?
  • When does SAB Biotherapeutics report earnings?
  • Should I buy SAB Biotherapeutics stock now?

What is the ticker symbol for SAB Biotherapeutics?

The ticker symbol for SAB Biotherapeutics is NASDAQ:SABS

Does SAB Biotherapeutics pay dividends?

No, SAB Biotherapeutics does not pay dividends

What sector is SAB Biotherapeutics in?

SAB Biotherapeutics is in the Healthcare sector

What industry is SAB Biotherapeutics in?

SAB Biotherapeutics is in the Biotechnology industry

What country is SAB Biotherapeutics based in?

SAB Biotherapeutics is headquartered in United States

When did SAB Biotherapeutics go public?

SAB Biotherapeutics's initial public offering (IPO) was on February 9, 2021

Is SAB Biotherapeutics in the S&P 500?

No, SAB Biotherapeutics is not included in the S&P 500 index

Is SAB Biotherapeutics in the NASDAQ 100?

No, SAB Biotherapeutics is not included in the NASDAQ 100 index

Is SAB Biotherapeutics in the Dow Jones?

No, SAB Biotherapeutics is not included in the Dow Jones index

When was SAB Biotherapeutics's last earnings report?

SAB Biotherapeutics's most recent earnings report was on Mar 31, 2025

When does SAB Biotherapeutics report earnings?

The next expected earnings date for SAB Biotherapeutics is May 20, 2025

Should I buy SAB Biotherapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page